Two federal lawmakers this week introduced bipartisan legislation that would extend 340B eligibility to certain outpatient-focused rural hospitals offering emergency [...] …
Year: 2024
As 340B stakeholders continue to hold out for long-awaited congressional action that could overhaul the discount drug pricing program, some [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Medicare Part D plans and 340B providers may avoid drugs with negotiated lower Medicare prices to maximize revenue from rebates, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Q: Where did you grow up?
I grew up in southern Connecticut and lived there my entire childhood.
Q: What are your favorites?
Food: Indian, pizza, soft-serve
…
SPONSORED CONTENT
TIP: If your entity has not been submitting data to 340B ESP or designating pharmacies associated with certain manufacturers, it may be time
Just weeks after passing legislation to prohibit drugmaker 340B contract pharmacy restrictions in the state, Kansas lawmakers voted late Tuesday [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Missouri Senate yesterday overwhelmingly passed a 340B contract pharmacy access bill, two weeks after the state house passed a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Louisiana’s 340B contract pharmacy access law is constitutional because it governs drug distribution and not pricing, a state official and [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The 340B program remains essential in ensuring equitable access to crucial medications for vulnerable, underserved populations. The program provides safety net providers with critical resources necessary to expand health related services to low-income and uninsured individuals. Over the past decade, controversy, criticism, and disagreement between manufacturers and program participants, along with regulatory agency indecision, has put the 340B program’s longevity and efficacy into question. To secure its sustainability, all 340B stakeholders must embrace a paradigm shift. Outmoded practices of mistrust and secrecy among stakeholders serve as obstacles to progress and must give way to transparency and collaboration.
Challenges to Sustainability
The sustainability of the 340B program, which is primarily funded through significant discounts from pharmaceutical manufacturers, faces major hurdles if the program continues to be perceived by manufacturers as expanding well beyond the program’s original scope and intent. The program’s expansion, driven by the Affordable Care Act (ACA), has significantly
…
A federal judge denied health insurer Humana’s request to dismiss an Alabama health system’s suit against its Medicare Advantage plans [...] …